Skip to main content

Table 2 Cerebrospinal fluid levels of the biomarker panel in the diagnostic groups

From: Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

Biomarker OND PD PDD DLB AD p Value
FABP3, pg/ml 521.6 (354.93) 491.5 (231.3) 738.2 (410.0) 836.3 (450.6)a,b 896.1 (514.07)c,d <0.001
α-Syn, pg/ml 1628.0 (705.4) 1846.3 (1216.7) 1381.8 (548.8) 1751.1 (1105.3) 2450.8 (871.24)c,d,e,f <0.001
t-tau, pg/ml 225.9 (114.6) 199.8 (73.9) 292.5 (153.5) 356.7 (176.9)a,b 669.8 (304.0)c,d,e,f <0.001
p-tau, pg/ml 45.7 (13.0) 44.6 (9.5) 55.0 (18.8) 60.2 (20.9)b 106.1 (37.3)c,d,e,f <0.001
1–42, pg/ml 813.0 (348.7) 792.3 (345.4) 533.8 (168.9)g,h 562.1 (249.4)a,b 465.0 (159.3)c,d <0.001
1–42-positive, <500 pg/ml 7/34 (17.1%) 13/41 (24.1%) 8/11 (42.1%) 15/25 (37.5%) 32/16 (67.7%) <0.001
  1. Abbreviations: Aβ 1–42 Amyloid-β peptide 1–42, AD Alzheimer’s disease, DLB Dementia with Lewy bodies, FABP3 Fatty acid binding protein 3, heart type, OND Other neurological diseases, PD Parkinson’s disease, PDD Parkinson’s disease with dementia, p-tau 181 Phosphorylated tau 181, α-syn α-Synuclein, t-tau Total tau
  2. The cerebrospinal fluid levels of all the tested biomarkers are reported. All data are reported as mean (SD). The p values in the table are relative to the general nonparametric analysis of variance test (across all groups), whereas the footnote callouts are relative to the within-group comparisons
  3. aDLB vs. OND
  4. bDLB vs. PD
  5. cAD vs. OND
  6. dAD vs. PD
  7. eAD vs. DLB
  8. fAD vs. PDD
  9. gPD vs. PDD
  10. hPDD vs. OND